Compare AbbVie Inc (ABBV) vs Eni SpA (E) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Eni SpA — how do they compare? AbbVie Inc trades at $248.11 (market cap $438.19B), while Eni SpA trades at $55.44 (market cap $78.80B). The key difference: AbbVie Inc is far larger — about 5.6× Eni SpA's market cap, and Eni SpA pays the higher dividend (4.45%). Which is the better fit depends on your goals.
| ABBV | E | |
|---|---|---|
Market Cap | $438.19B | $78.80B |
Sector | Health | Energy |
52-Week High | $263.58 | $57.61 |
52-Week Low | $197.38 | $34.03 |
Enterprise Value | $502.45B | $104.11B |
Dividend Yield | 2.79% | 4.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $248.47, up 0.99% with a bullish technical signal supported by moving averages and oversold RSI levels. The company demonstrates strong revenue growth with 2025 revenue reaching $61.16B and consistent earnings beats in recent quarters. Recent positive clinical trial results for ovarian cancer treatment and institutional accumulation signal confidence in the company's pipeline and growth trajectory.
AbbVie presents a compelling investment case with 71% analyst buy ratings and a $281.33 consensus price target offering 13% upside. Key risks include patent cliffs in the 2030s and high debt levels, but robust immunology portfolio growth and dividend aristocrat status provide stability. The stock's current valuation metrics suggest premium pricing relative to historical levels.
Eni (E) trades at $53.61, down 1.22% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent Q2 2026 earnings missed estimates despite 21.5% revenue growth, while the company increased its share buyback program. Valuation ratios appear attractive with a P/E of 12.08 and P/S of 0.79. Cash flow from operations remains strong at $13.33 billion for 2025, supporting dividend payments and strategic investments.
The outlook for Eni is cautiously optimistic, driven by production growth and strategic partnerships, but faces risks from commodity price volatility and geopolitical factors. Analyst consensus is mixed with 34.62% buy ratings, highlighting potential upside if operational execution improves and energy markets stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
